Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)
WAYNE, Pa. and ROCKVILLE, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced that the first patient has been dosed in the company’s Phase 2 PEAK (A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma K) trial evaluating AVTX-002 for the treatment of non-eosinophilic asthma (NEA).
“Dosing the first patient in the Phase 2 PEAK trial brings us a step closer to delivering a new treatment option to these patients. Nearly half of all asthma patients have NEA, for which there is no specific treatment currently approved,” said Garry A. Neil, MD, President and Chief Executive Officer, Avalo Therapeutics.
Phase 2 Trial
About Avalo Therapeutics
For more information about Avalo, please visit www.avalotx.com.